Paliperidone ER

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaAutismPsychosisSchizoaffective DisorderBipolar I Disorder

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Paliperidone ER

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved

282

Celexa

AbbVie

Preclinical

43

Inapsine

Alnylam Pharmaceuticals

Preclinical

14

Ozempic

Novo Nordisk

Preclinical

15

Resotran

Takeda

Preclinical

16

Zocor

OOrganon and Co

Preclinical

67

Depakote

AbbVie

Preclinical

—8

Ibrance

Pfizer

Preclinical

—9

Lunesta

Akero Therapeutics

Preclinical

310

Permax

VValeant Pharmaceuticals

Preclinical

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia28 trials

Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00077714·12 enrolled

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Completed·JJohnson & Johnson Taiwan Ltd·Phase 4·NCT00757705·299 enrolled

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Completed·Johnson & Johnson·Phase 3·NCT01541371·405 enrolled

Show 25 more trials

Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER

Completed·TTaipei City Hospital·Phase 4·NCT02075528·41 enrolled

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00078039·630 enrolled

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Terminated·Johnson & Johnson·Phase 4·NCT00934635·2 enrolled

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Completed·Johnson & Johnson·Phase 3·NCT00645099·462 enrolled

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00518323·201 enrolled

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Completed·Johnson & Johnson·Phase 3·NCT01662648·1,117 enrolled

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Completed·—·Phase 4·NCT00827840·58 enrolled

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Completed·JJohnson & Johnson Taiwan Ltd·Phase 4·NCT01577160·353 enrolled

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Completed·Johnson & Johnson·Phase 4·NCT01362439·133 enrolled

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00085748·114 enrolled

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

Completed·Johnson & Johnson·Phase 4·NCT01724359·95 enrolled

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

Completed·Johnson & Johnson··NCT00697658·27 enrolled

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00086320·111 enrolled

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

Completed·Johnson & Johnson·Phase 3·NCT00460512·1,814 enrolled

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Completed·Johnson & Johnson·Phase 3·NCT01606228·188 enrolled

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00535132·201 enrolled

Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00105326·5 enrolled

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00524043·201 enrolled

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210769·203 enrolled

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01150448·212 enrolled

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00752427·86 enrolled

Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00083668·619 enrolled

The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia

Terminated·Johnson & Johnson··NCT00488891·43 enrolled

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Completed·Johnson & Johnson·Phase 3·NCT00488319·400 enrolled

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Completed·Johnson & Johnson·Phase 3·NCT02431702·337 enrolled

Lip5 trials

A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00790777·72 enrolled

A Pharmacokinetic Study of Paliperidone ER

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT02433717·40 enrolled

Different Safety Profile of Risperidone and Paliperidone Extended-release

Completed·—·Phase 4·NCT01284959·34 enrolled

Show 2 more trials

A Study of the Dose Proportionality of Extended Release Paliperidone

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791167·58 enrolled

A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791193·80 enrolled

Bipolar I Disorder4 trials

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00309699·493 enrolled

A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00892125·64 enrolled

A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00309686·300 enrolled

Show 1 more trial

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00490971·768 enrolled

Tics3 trials

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00796185·62 enrolled

A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791713·60 enrolled

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00796471·35 enrolled

Schizoaffective Disorder2 trials

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00412373·307 enrolled

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00397033·316 enrolled

7 more indications

Interaction1 trial

A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01060228·24 enrolled

Remission1 trial

Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

Completed·JJohnson & Johnson Taiwan Ltd·Phase 4·NCT01577186·480 enrolled

Agitation1 trial

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Completed·Johnson & Johnson·Phase 4·NCT01050478·56 enrolled

Autism1 trial

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Completed·IIndiana University School of Medicine·Phase 3·NCT00549562·25 enrolled

ALS1 trial

A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791622·110 enrolled

Psychosis1 trial

Efficacy and Safety of Paliperidone ER in First Episode Psychosis

Completed·—·Phase 4·NCT01157585·75 enrolled

Single Dose1 trial

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00758030·60 enrolled

Details

Drug Info

Related News